# Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

> **NCT05009836** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hutchison Medipharma Limited** · enrollment: 320 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Savolitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05009836
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-06
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009836, "Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05009836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*